Heidi Glosli

Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial

Gianni Bisogno, Gian Luca De Salvo, Christophe Bergeron et al. · The Lancet Oncology · 2019 · 231 citations · Full text

Oncology, Metronomic Therapy, Rms 2005 +9

Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

Gianni Bisogno, Meriel Jenney, Christophe Bergeron et al. · The Lancet Oncology · 2018 · 182 citations

Oncology, Medicine, Dose-intensified Doxorubicin +10

Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial

Leonardo R. Brandão, Matteo Luciani, Lisa Bomgaars et al. · The Lancet Haematology · 2020 · 134 citations · Full text

Thrombosis, Venous Disease, Venous Thrombosis +8

Fusion status in patients with lymph node‐positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Soledad Gallego, Ilaria Zanetti, Daniel Orbach et al. · Cancer · 2018 · 80 citations · Full text

Early and treatment‐related deaths in childhood acute myeloid leukaemia in the Nordic countries: 1984–2003

Lene Molgaard‐Hansen, Merja Möttönen, Heidi Glosli et al. · British Journal of Haematology · 2010 · 56 citations · Full text